SECTOR:
CNS
FUND/VEHICLE:
Pivotal US
INVESTMENT DATE:
2019
GEOGRAPHY:
North America
STATUS CURRENT/FORMER INVESTMENT:
Existing
WEBSITE:
Karuna Therapeutics is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.